Junhong Han

Dr. Junhong Han

West China School of Medicine, Sichuan University, Chengdu, China
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2007 in Nature
Verified
Journal Article
Closed access
PDF file
SCSean R. Collins
Sean R. Collins
KMKyle Miller
Kyle Miller
NMNancy L. Maas
Nancy L. Maas
ARAssen Roguev
Assen Roguev
JFJeffrey Fillingham
Jeffrey Fillingham
NKNevan J. Krogan
Nevan J. Krogan

2 February 2007 in Science
Verified
Journal Article
Closed access
PDF file
Junhong HanJunhong Han
Junhong Han
HZHui Zhou
Hui Zhou
BHBruce Horazdovsky
Bruce Horazdovsky
Kangling ZhangKangling Zhang
Kangling Zhang
RXRui-Ming Xu
Rui-Ming Xu
ZZZhiguo Zhang
Zhiguo Zhang
Acetylation of histone H3 lysine 56 (H3-K56) occurs in S phase, and cells lacking H3-K56 acetylation are sensitive to DNA-damaging agents. However, the histone acetyltransferase (HAT) that catalyzes global H3-K56 acetylation has not been found. Here we show that regulation of Ty1 transposition gene product 109 (Rtt109) is an H3-K56 HAT. Cells lacking Rtt109 or expressing rtt109 mutants with alterations at a conserved aspartate residue lose H3-K56 acetylation and exhibit increased sensitivity toward genotoxic agents, as well as elevated levels of spontaneous chromosome breaks. Thus, Rtt109, which shares no sequence homology with any other known HATs, is a unique HAT that acetylates H3-K56.

1 November 2014 in Molecular Cell
Verified
Journal Article
Closed access
CYChuanhe Yu
Chuanhe Yu
HGHaiyun Gan
Haiyun Gan
Junhong HanJunhong Han
Junhong Han
ZZZhi-Xiong Zhou
Zhi-Xiong Zhou
SJShaodong Jia
Shaodong Jia
ZZZhiguo Zhang
Zhiguo Zhang

24 August 2023 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
LQLei Qiu
Lei Qiu
QJQian Jing
Qian Jing
YLYanbo Li
Yanbo Li
Junhong HanJunhong Han
Junhong Han
RNA modifications are dynamic and reversible chemical modifications on substrate RNA that are regulated by specific modifying enzymes. They play important roles in the regulation of many biological processes in various diseases, such as the development of cancer and other diseases. With the help of advanced sequencing technologies, the role of RNA modifications has caught increasing attention in human diseases in scientific research. In this review, we briefly summarized the basic mechanisms of several common RNA modifications, including m6A, m5C, m1A, m7G, Ψ, A-to-I editing and ac4C. Importantly, we discussed their potential functions in human diseases, including cancer, neurological disorders, cardiovascular diseases, metabolic diseases, genetic and developmental diseases, as well as immune disorders. Through the “writing-erasing-reading” mechanisms, RNA modifications regulate the stability, translation, and localization of pivotal disease-related mRNAs to manipulate disease development. Moreover, we also highlighted in this review all currently available RNA-modifier-targeting small molecular inhibitors or activators, most of which are designed against m6A-related enzymes, such as METTL3, FTO and ALKBH5. This review provides clues for potential clinical therapy as well as future study directions in the RNA modification field. More in-depth studies on RNA modifications, their roles in human diseases and further development of their inhibitors or activators are needed for a thorough understanding of epitranscriptomics as well as diagnosis, treatment, and prognosis of human diseases.

1 September 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Junhong HanJunhong Han
Junhong Han
HZHui Zhou
Hui Zhou
ZLZhizhong Li
Zhizhong Li
RXRui-Ming Xu
Rui-Ming Xu
ZZZhiguo Zhang
Zhiguo Zhang
In budding yeast, acetylation of histone H3 lysine 56 (H3-K56) is catalyzed by the Rtt109-Vps75 histone acetyltransferase (HAT) complex, with Rtt109 being the catalytic subunit, and histone chaperone Asf1 is required for this modification. Cells lacking Rtt109 are susceptible to perturbations in DNA replication. However, how Asf1 regulates acetylation of H3-K56 and how loss of H3-K56 acetylation affects DNA replication are unclear. We show that at low concentrations the Rtt109-Vps75 HAT complex acetylates H3-K56 in vitro when H3/H4 is complexed with Asf1, but not H3/H4 tetramers, recapitulating the in vivo requirement of Asf1 for H3-K56 acetylation using recombinant proteins. Moreover, the Rtt109-Vps75 complex interacts with Asf1-H3/H4 but not Asf1. In vivo, the Rtt109-Asf1 interaction is also dependent on the ability of Asf1 to bind H3/H4. Furthermore, the Rtt109 homolog in Schizosaccharomyces pombe (SpRtt109) also displayed an Asf1-dependent H3-K56 HAT activity in vitro. These results indicate that Asf1 regulates H3-K56 acetylation by presenting histones H3 and H4 to Rtt109-Vps575 for acetylation, and this mechanism is likely to be conserved. Finally, we have shown that cells lacking Rtt109 or expressing H3-K56 mutants exhibited significant reduction in the association of three proteins with stalled DNA replication forks and hyper-recombination of replication forks stalled at replication fork barriers of the ribosomal DNA locus compared with wild-type cells. Taken together, these studies provide novel insight into the role of Asf1 in the regulation of H3-K56 acetylation and the function of this modification in DNA replication.

1 February 2010 in Molecular Cell
Verified
Journal Article
Closed access
RBRebecca J. Burgess
Rebecca J. Burgess
HZHui Zhou
Hui Zhou
Junhong HanJunhong Han
Junhong Han
ZZZhiguo Zhang
Zhiguo Zhang